Bloom Burton Comments on Zymeworks FY2025 Earnings

Zymeworks Inc. (NYSE:ZYME) – Investment analysts at Bloom Burton issued their FY2025 EPS estimates for Zymeworks in a report issued on Wednesday, September 3rd. Bloom Burton analyst D. Martin anticipates that the company will earn ($1.13) per share for the year. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Bloom Burton also issued estimates for Zymeworks’ FY2026 earnings at ($1.93) EPS and FY2027 earnings at ($2.11) EPS.

Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.55. The firm had revenue of $48.73 million for the quarter, compared to analysts’ expectations of $17.18 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business’s quarterly revenue was up 153.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.49) earnings per share.

A number of other research analysts have also recently commented on ZYME. HC Wainwright reissued a “neutral” rating and issued a $13.00 target price on shares of Zymeworks in a research note on Thursday, July 3rd. Citigroup increased their target price on Zymeworks from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, August 11th. TD Cowen assumed coverage on Zymeworks in a research note on Tuesday, May 20th. They issued a “buy” rating on the stock. Finally, TD Securities assumed coverage on Zymeworks in a research note on Tuesday, May 20th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.43.

Zymeworks Stock Performance

Zymeworks stock opened at $15.05 on Friday. The stock has a market cap of $1.13 billion, a P/E ratio of -10.03 and a beta of 1.27. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $17.70. The firm’s fifty day moving average price is $13.63 and its 200-day moving average price is $12.66.

Institutional Trading of Zymeworks

Institutional investors have recently modified their holdings of the company. CWM LLC boosted its holdings in shares of Zymeworks by 1,091.2% during the first quarter. CWM LLC now owns 2,299 shares of the company’s stock worth $27,000 after purchasing an additional 2,106 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Zymeworks by 29.6% during the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after purchasing an additional 1,131 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Zymeworks by 1,113.3% during the first quarter. GAMMA Investing LLC now owns 6,467 shares of the company’s stock worth $77,000 after purchasing an additional 5,934 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Zymeworks during the fourth quarter worth about $108,000. Finally, Northwest & Ethical Investments L.P. boosted its holdings in shares of Zymeworks by 83.3% during the first quarter. Northwest & Ethical Investments L.P. now owns 10,030 shares of the company’s stock worth $119,000 after purchasing an additional 4,559 shares during the period. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.